Rituximab improved dexamethasone response rates in immune thrombocytopeniaHealioResearchers randomly assigned 71 patients to dexamethasone 40 mg/day for 4 days, and 62 patients were assigned this dexamethasone regimen plus rituximab (Rituxan, Genentech…
 Daily Mail |
The great cancer betrayal: Number of treatments on approved list for patients …
Daily Mail The blood cancer drug, Rituximab, was the fourth most frequently requested treatment through the Fund last year. Andrew Wilson, chief executive of the Rarer Cancers Foundation, said: ‘This appears to be a clear step backwards for cancer patients in … |
|
TIME, TIME Warner ethical questions raised in cancer coverage
HealthNewsReview.org $13,702 for rituximab injection – “a cancer wonder drug called Rituxan…MD Anderson probably gets a volume discount that would make its cost $3,000 to $3,500.” “The president of MD Anderson is paid like someone running a prosperous business. Ronald … |
B-cell targeted therapeutics in clinical development7thSpace Interactive (press release)B-cell depletion with the CD20 antibody rituximab has provided clinical proof of concept that targeting B cells and the humoral response can result in significant b…
Biologic therapy for autoimmune diseases: an update7thSpace Interactive (press release)This review provides an update of the recent literature on the new biologic therapies available. The review concentrates on nine drugs: tocilizumab, rituximab, ofatu…
 In-PharmaTechnologist.com |
Lonza Reaffirms Commitment to Teva Biosimilars JV in Light of ‘Inaccurate …
In-PharmaTechnologist.com News of the strategy review follows a few months after Teva halted a Phase III trial of TL011 , a biosimilar version of Swiss drugmaker Roche’s Rituxan/MabThera (rituximab). According to a report in Israeli newspaper Haaretz at the time development was … |
Biosimilars Could Be An Unlikely Boost For PfizerSeeking AlphaIn this same earnings call Pfizer CEO also mentions that they are working on 3 other biosimilars but they are not nearly as far along on those molecules as Trastuzumab and Rituximab. As an i…
|
Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®
PharmiWeb.com (press release) … three principal products AVONEX® (interferon beta-1a) TYSABRI and RITUXAN® (rituximab) the importance of TYSABRI’s sales growth uncertainty of success in commercializing and developing other products product competition the occurrence of adverse … |
 Genetic Engineering News |
Electronics Giants Set Sights on Biotech
Genetic Engineering News Last October, the company halted development of a biosimilar version of the Roche/Biogen Idec lymphoma and rheumatoid arthritis drug Rituxan (rituximab)—just six months after Tae-Han Kim, president of Samsung Biologics, told the Financial Times the … |
Genetic Engineering News |
Electronics Giants Think Biotech
Genetic Engineering News Last October, the company halted development of a biosimilar version of the Roche/Biogen Idec lymphoma and rheumatoid arthritis drug Rituxan (rituximab)—just six months after Tae-Han Kim, president of Samsung Biologics, told the Financial Times the … |